Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy

As Sangamo runs out of cash, Eli Lilly and Astellas have emerged as stalking horse bidders for key assets, including a Fabry gene therapy currently being submitted for potential FDA approval.